Effects of thymidine phosphorylase levels in cancer, background mucosa, and regional lymph nodes on survival of advanced gastric cancer patients receiving postoperative fluoropyrimidine therapy

Oncology Reports

Volumn 12, Issue 6, 2004, Pages 1279-1286

  Kosaka, Takeo ^a   Usami, Kazuo ^a   Ueshige, Nobuo ^a   Sugaya, Junichi ^a   Nakano, Yasuharu ^a   Takashima, Shigeki ^a  

^a KANAZAWA MEDICAL UNIVERSITY   (Japan)

Author keywords

Fluoropyrimidine; Gastric cancer; Survival; Thymidine phosphorylase

Indexed keywords

ANTINEOPLASTIC ANTIMETABOLITE; THYMIDINE PHOSPHORYLASE;

ADULT; AGED; ARTICLE; COMPARATIVE STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYMOLOGY; FEMALE; GASTRECTOMY; HUMAN; LYMPH NODE; LYMPH NODE METASTASIS; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; STOMACH MUCOSA; STOMACH TUMOR; SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GASTRECTOMY; GASTRIC MUCOSA; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; PROGNOSIS; STOMACH NEOPLASMS; SURVIVAL; THYMIDINE PHOSPHORYLASE;

EID: 16644399118     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.12.6.1279     Document Type: Article

References (43)

1. Heggie GD, Sommadossi JP, Cross DS, Huster WJ and Diasio RB: Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res 47: 2203-2206, 1987. (Pubitemid 17074634)
2. Rustum YM: Biochemical rationale for the 5-fluorouracil leucovorin combination and update of clinical experience. J Chemother 2 (suppl 1): 5-11, 1990.
3. Ardalan B and Glazer R: An update on the biochemistry of 5-fluorouracil. Cancer Treat Rev 8: 157-167, 1981. (Pubitemid 12197755)
4. Kono A, Hara Y, Sugata S, Karube Y, Matsushima Y and Ishitsuka H: Activation of 5′-deoxy-5-fluorouridine by thymidine phosphorylase in human tumors. Chem Pharm Bull 31: 175-178, 1983. (Pubitemid 13122231)
5. Patterson AV, Zhang H, Moghaddam A, Bicknell R, Talbot DC, Stratford IJ and Harris AL: Increased sensitivity to the prodrug 5′-deoxy-5- fluorouridine and modulation of 5-fluoro-2′-deoxyuridine sensitivity in MCF-7 cells transfected with thymidine phosphorylase. Br J Cancer 72: 669-675, 1995.
6. Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K,\ Shimma N, Umeda I and Ishitsuka H: Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 34: 1274-1281, 1998. (Pubitemid 28342121)
7. Ciccolini J, Evrard A and Cuq P: Thymidine phosphorylase and fluoropyrimidines efficacy: a jekyl and hyde story. Curr Med Chem Anti-Cancer Agents 4: 71-81, 2004.
8. Takebayashi Y, Akiyama S, Akiba S, Yamada K, Miyadera K, Sumizawa T, Yamada Y, Murata F and Aikou T: Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase, in human colorectal carcinoma. J Natl Cancer Inst 88: 1110-1117, 1996. (Pubitemid 26274605)
9. Ishii R, Takiguchi N, Oda K, Koda K and Miyazaki M: Thymidine phosphorylase expression is useful in selecting adjuvant chemotherapy for stage III gastric cancer. Int J Oncol 19: 717-722, 2001.
10. Konno S, Takebayashi Y, Aiba M, Akiyama S and Ogawa K: Clinicopathological and prognostic significance of thymidine phosphorylase and proliferating cell nuclear antigen in gastric carcinoma. Cancer Lett 166: 103-111, 2001. (Pubitemid 32274291)
11. Kimura H, Konishi K, Kaji M, Maeda K, Yabushita K and Miwa A: Correlation between expression levels of thymidine phosphorylase (dThdPase) and clinical features in human gastric carcinoma. Hepatogastroenterology 49: 882-886, 2002. (Pubitemid 34615371)
12. Konno S, Takebayashi Y, Higashimoto M, Kalsube T, Kanzaki A, Kawahara M, Takenoshita S, Aiba M and Ogawa K: Thymidine phosphorylase expression in gastric carcinoma as a marker for metastasis. Anticancer Res 23: 5011-5014, 2003. (Pubitemid 38182118)
13. Japanese Research Society for Gastric Cancer: Japanese classification of gastric carcinoma, 1st English Edition, Kanehara, Tokyo, 1995.
14. Nishida M, Hino A, Mori K, Matsumoto T, Yoshikubo T and Ishitsuka H: Preparation of anti-human thymidine phosphorylase monoclonal antibodies useful for detecting the enzyme levels in tumor tissues. Biol Pharm Bull 19: 1407-1411, 1996. (Pubitemid 26403242)
15. Sugiyama A, Maruta F, Tsuzuki S, Murakami M and Kawasaki S: Distribution of thymidine phosphorylase activity in gastric carcinoma and adjacent normal gastric tissue. Hepatogastroenterology 49: 1734-1736, 2002. (Pubitemid 35277372)
16. Katayanagi S, Aoki T, Takagi Y, Ito K, Sudo H, Tsuchida A and Koyanagi Y: Measurement of serum thymidine phosphorylase levels by highly sensitive enzyme-linked immunosorbent assay in gastric cancer. Oncol Rep 10: 115-119, 2003.
17. Takebayashi Y, Yamada K, Miyadera K, Sumizawa T, Furukawa T, Kinoshita F, Aoki D, Okumura H, Yamada Y, Akiyama S and Aikou T: The activity and expression in human solid tumors. Eur J Cancer 32A: 1227-1232, 1996.
18. Morinaga S, Yamamoto Y, Noguchi Y, Imada T, Rino Y, Akaike M, Sugimasa Y, Takemiya S and Takanashi Y: Platelet-derived endothelial cell growth factor (PD-ECGF) is up-regulated in human hepatocellular carcinoma (HCC) and the corresponding hepatitis liver. Hepatogastroenterology 50: 1521-1526, 2003. (Pubitemid 37186523)
19. Kinsui H, Ueda T, Suzuki H, Isaka S, Sekita N, Komiya A, Tobe T, Yamanishi T, Akakura K, Ichikawa T, Igarashi T and Ito H: Expression of thymidine phosphorylase in primary human renal cell carcinoma by ELISA method. Jpn J Cancer Res 93: 340-345, 2002. (Pubitemid 34464371)
20. Kikuno N, Yoshino T, Urakami S, Shigeno K, Kishi H, Hata K, Shiina H and Igawa M: The role of thymidine phosphorylase (TP) mRNA expression in angiogenesis of prostate cancer. Anticancer Res 23: 1305-1312, 2003. (Pubitemid 36754092)
21. Mizutani Y, Okada Y and Yoshida O: Expression of platelet-derived endotheial cell growth factor in bladder carcinoma. Cancer 79: 1190-1194, 1997. (Pubitemid 27118614)
22. Reynold K, Farzaneh F, Collins WP, Cambel S, Bourne TH, Lawton F, Moghaddam A, Harris AL and Bicknell R: Association of ovarian malignancy with expression of platelet-derived endothelial growth factor. J Natl Cancer Inst 86: 1234-1238, 1994. (Pubitemid 24253699)
23. Yano T and Takeo S: Thymidine phosphorylase activity in non-small cell lung carcinoma tissues. Cancer 92: 2658-2561, 2001.
24. Koizumi W, Saigenji K, Nakamaru N, Okayasu I and Kurihara M: Prediction of response to 5′-deoxy-5-fluorouridine (5′-DFUR) in patients with inoperable advanced gastric cancer by immunostaining of thymidine phosphorylase/platelet-derived endothelial cell growth factor. Oncology 56: 215-222, 1999. (Pubitemid 29161291)
25. Saito H, Tsujitani S, Oka S, Kondo A, Ikeguchi M, Maeta M and Kaibara N: The expression of thymidine phosphorylase correlates with angiogenesis and the efficacy of chemotherapy using fluorouracil derivatives in advanced gastric carcinoma. Br J Cancer 81: 484-489, 1999. (Pubitemid 29458803)
26. Kikuyama S, Inada T, Shimizu K, Miyakita M and Ogata Y: p53, bcl-2 and thymidine phosphorylase as predictive markers of chemotherapy in patients with advanced and recurrent gastric cancer. Anticancer Res 21: 2149-2153, 2001. (Pubitemid 32728882)
27. Takahashi Y, Bucana CD, Liu W, Yoneda J, Kitadai Y, Cleary KR and Ellis LM: Platelet-derived endothelial cell growth factor in human colon cancer angiogenesis: role of infiltrating cells. J Natl Cancer Inst 88: 1146-1151, 1996. (Pubitemid 26274608)
28. Saeki T, Tanada M, Takashima S, Saeki H, Takiyama W, Nishimoto N and Moriwaki S: Correlation between expression of platelet-derived endothelial cell growth factor (thymidine phosphorylase) and microvessel density in early-stage human colon carcinomas. Jpn J Clin Oncol 27: 227-230, 1997. (Pubitemid 127516769)
29. Zhang JM, Mizoi T, Shiiba K, Sasaki I and Matsuno S: Expression of thymidine phosphorylase by macrophages in colorectal cancer tissues. World J Gastroenterol 10: 545-549, 2004. (Pubitemid 38325312)
30. Tanaka T, Yoshiki T, Arai Y, Higuchi K, Kageyama S, Ogawa Y, Isono T and Okada Y: Expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in human bladder cancer. Jpn J Cancer Res 90: 1344-1350, 1999. (Pubitemid 30032073)
31. Ohta M, Kiladai Y, Tanaka S, Yoshihara M, Yasui W, Mukaida N, Haruma K and Chayama K: Monocyte chemo-attractant protein-1 expression correlates with macrophage infiltration and tumor vascularity in human gastric carcinomas. Int J Oncol 22: 773-778, 2003.
32. Takiguchi N, Ishii R, Koda K, Oda K and Miyazaki M: Thymidine phosphorylase expression correlates with malignant potential and anti-tumor effect of doxifluridine on gastric cancer: multivariate analysis for adjuvant chemotherapy doxifluridine vs. 5-fluorouracil. Oncol Rep 10: 1105-1111, 2003.
33. Noguchi T, Fujiwara S, Takeno S, Kai S, Mizuta A, Nagao Y and Uchida Y: Clinical impact of thymidine phosphorylase expression in gastric cancer. Oncol Rep 10: 561-566, 2003.
34. Mimori K, Matsuyama A, Yoshinaga K, Yamashita K, Masuda T, Inoue H, Ueo H and Mori M: Localization of thymidine phosphorylase expression in colorectal carcinoma tissues by in situ RT-PCR assay. Oncology 62: 327-332, 2002. (Pubitemid 34914102)
35. Terashima M, Fujiwara H, Takagane A, Abe K, Araya M, Irinoda T, Yonezawa H, Nakaya T, Oyama K, Takahashi M and Saito K: Role of thymidine phosphorylase and dihydropyrimidine dehydrogenase in tumour progression and sensitivity to doxifluridine in gastric cancer patients. Eur J Cancer 38: 2375-2381, 2002. (Pubitemid 35387489)
36. Kim R, Murakami S and Toge T: Effects of introduction of dThdPase cDNA on sensitivity to 5′-deoxy-5-fluorouridine and tumor angiogenesis. Int J Oncol 22: 835-841, 2003.
37. de Bruin M, van Capel T, Van der Born K, Kruyt FA, Fukushima M, Hoekman K, Pinedo HM and Peters GJ: Role of platelet-derived endothelial cell growth factor/thymidine phosphorylase in fluoropyrimidine sensitivity. Br J Cancer 88: 957-964, 2003. (Pubitemid 36520887)
38. Ma T, Zhu ZG, Ji YB, Zhang Y, Yu YY, Liu BY, Yin HR and Lin YZ: Correlation of thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase with sensitivity of gastrointestinal cancer cells to 5-fluorouracil and 5-fluoro-2′-deoxyuridine. World J Gastroenterol 10: 172-176, 2004. (Pubitemid 38195255)
39. Zhang J, Mizoi T, Harada N, Shiiba K, Miyagawa K, Matsuno S and Sasaki I: Thymidine phosphorylase expressed in macrophages enhances antitumor effect of 5′-deoxy-5-fluorouridine on human colorectal carcinoma cells. Anticancer Res 23: 323-329, 2003. (Pubitemid 36358535)
40. Johnston PG, Lenz HJ, Leichman CG, Danenberg KD, Allegra GI, Danenberg PV and Leichman L: Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 55: 1407-1412, 1995.
41. Lenz HJ, Leichman CG, Danenberg KD, Danenberg PV, Groshen S, Cohen H, Laine L, Crookes P, Silberman H, Baranda J, Garcia Y, Li J and Leichman L: Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival. J Clin Oncol 14: 176-182, 1996. (Pubitemid 26020011)
42. Leichman CG, Lenz HJ, Leichman L, Danenberg K, Baranda J, Groshen S, Boswell W, Metzger R, Tan M and Danenberg PV: Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J Clin Oncol 15: 3223-3229, 1997. (Pubitemid 27419335)
43. Etienne MC, Cheradame S, Fischel JL, Formento P, Dassonville O, Renee N, Schneider M, Thyss A, Demard F and Milano G: Response to fluorouracil therapy in cancer patients: the role of tumoral dihydropyrimidine dehydrogenase activity. J Clin Oncol 13: 1663-1670, 1995.